Foamix pharmaceuticals ltd. (FOMX)
Income statement / Quarterly
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Jun'16Jun'15Jun'14
REVENUES (Note 13b)

135

0

0

308

860

865

964

906

1,043

901

798

927

752

109

598

COST OF REVENUES

-

-

-

-

-

-

-

-

-

11

-

-

12

13

137

GROSS PROFIT

-

-

-

-

-

-

-

-

-

890

-

-

740

96

461

OPERATING EXPENSES:
Research and development

15,346

12,452

12,556

10,848

11,665

13,142

16,842

22,825

15,379

15,785

13,940

12,675

6,734

2,795

353

Selling, general and administrative

22,220

10,747

6,803

5,344

3,994

3,309

2,909

3,801

2,285

2,933

3,451

2,822

2,128

2,023

409

TOTAL OPERATING EXPENSES

37,566

23,199

19,359

16,192

15,659

16,451

19,751

26,626

17,664

18,718

17,391

15,497

8,862

4,818

762

OPERATING LOSS

-37,431

-23,199

-19,359

-15,884

-14,799

-15,586

-18,787

-25,720

-16,623

-17,828

-16,593

-14,570

-8,122

-4,722

-301

FINANCE INCOME (Note 13c)

764

38

366

504

514

119

279

73

288

302

287

257

-14

83

-3,131

LOSS BEFORE INCOME TAX

-37,820

-23,161

-18,993

-15,380

-14,329

-15,467

-18,508

-25,647

-16,406

-17,526

-16,306

-14,313

-8,136

-4,639

-

INCOME TAX (Note 12)

0

0

0

-176

-251

13

120

330

955

57

81

71

57

8

0

NET LOSS FOR THE YEAR

-37,820

-23,161

-18,993

-15,204

-14,078

-15,480

-18,628

-25,977

-17,361

-17,583

-16,387

-14,384

-8,193

-4,647

-3,432

LOSS PER SHARE BASIC AND DILUTED

0.62

0.41

0.35

0.28

0.17

0.38

0.46

0.69

0.46

0.47

0.44

0.39

0.27

0.18

0.30

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE IN THOUSANDS

64,388

55,984

54,426

54,370

56,124

40,873

40,102

37,541

37,465

37,431

37,420

37,188

30,661

25,917

11,408